Saturday, November 27

▷ Breakthrough data set to fight heart disease


01.11.2021 – 12:00

Protodigm

London (ots/PRNewswire)

– The Thrombosis Research Institute and Protodigm are building a comprehensive research class data set of the first dedicated prospective global cohort of patients with multiple cardiovascular incidents using advanced clinical follow-up, multi-automatic analysis, and longitudinal physiological monitoring to provide insights for the To win the development of precision medicine in the fight against cardiovascular disease

– Life sciences companies are invited to join this global alliance

Protodigm today announced the start of a groundbreaking patient study that will work with the Thrombosis Research Institute (TRI) to bring true precision medicine to the fight against cardiovascular disease.

  • With its academic and clinical thought leadership and therapeutic insight into cardiovascular disease, TRI will lead the study, provide a global committee, host the database and biobank, and leverage its established clinical trial network of over 2000 locations in 35 countries that previously included GARFIELD AF- and implemented VTE programs. It will enable intensive interrogation of the data set using advanced data science techniques, including the development of “digital twins” and machine learning algorithms.
  • Protodigm will provide pharmaceutical compounds and asymmetric learning to the study datasets to generate unique insights and knowledge gaps, create learning plans, and identify potential therapeutic pathways.

Despite decades of intensive but traditional research, cardiovascular diseases are still one of the greatest global health burdens. The next advances will come from the application of next generation data science techniques to the prospective collection and retrieval of data derived from a multidimensional, integrated global population of cardiovascular patients observed over an extended period of time will.

“This project represents a unique opportunity to monitor a diverse group of patients, gain new knowledge and improve outcomes in cardiovascular disease worldwide,” said Professor Lord Kakkar, President of the Thrombosis Research Institute.

“Protodigm is committed to applying leading advances in data science and learning to accelerate knowledge-driven innovation. Working with TRI provides a unique opportunity to demonstrate that concept. This project will be the future of big data science for ours Shaping the industry, “said Mike Rea, CEO of Protodigm.

Protodigm and TRI invite biotech and pharmaceutical companies to join a pre-competitive alliance that offers the opportunity to work on an exciting global cardiovascular project. The study will run for 4 years.

Companies interested in joining the alliance can contact Tara Raveendran at Protodigm.

Information on Protodigm:

Protodigm is a Skunkworks company that provides its customers with a research facility to develop and innovate new products. Protodigm uses Skunkworks techniques in drug development to provide customers with all possible development options by hypothesizing and providing evidence. This approach breaks with industry conventions, because drug development is all too often a risky, one-way process. The failure of a system can have devastating consequences. With a Skunkworks approach, assets can be developed with multiple parallel options in addition to their original purpose, which lowers the innovation risk and saves time, money and effort.

Learn more about Protodigm on www.protodigm.co.

Press contact:

Scott Stachowiak
Campbell Partners, LLC
[email protected]
+1 (646) 942-5630
Logo – https://mma.prnewswire.com/media/1512148/Protodigm_Logo.jpg

Original content by: Protodigm, transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published. Required fields are marked *